Literature DB >> 23390288

Quantification of viral loads lower than 50 copies per milliliter by use of the Cobas AmpliPrep/Cobas TaqMan HIV-1 test, version 2.0, can predict the likelihood of subsequent virological rebound to >50 copies per milliliter.

Marta Álvarez Estévez1, Natalia Chueca Porcuna, Vicente Guillot Suay, Alejandro Peña Monge, Fernando García García, Leopoldo Muñoz Medina, David Vinuesa García, Jorge Parra Ruiz, Jose Hernández-Quero, Federico García García.   

Abstract

After 1 year of follow-up, patients on HAART with a baseline viral load (VL) of <20 copies/ml showed significantly lower odds of virological rebound to two consecutive VLs of >50 copies/ml than those with baseline VLs of 20 to 39 and 40 to 49 (P < 0.001). The time to virological rebound was also significantly shorter (P < 0.001) for the groups with baseline VLs of 20 to 39 and 40 to 49.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23390288      PMCID： PMC3647906          DOI： 10.1128/JCM.00100-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  13 in total

1.  Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy.

Authors:  Tomas Doyle; Colette Smith; Paola Vitiello; Valentina Cambiano; Margaret Johnson; Andrew Owen; Andrew N Phillips; Anna Maria Geretti
Journal:  Clin Infect Dis       Date:  2012-01-11       Impact factor: 9.079

2.  Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome.

Authors:  Charlotte Charpentier; Roland Landman; Cédric Laouénan; Véronique Joly; Gwenn Hamet; Florence Damond; Françoise Brun-Vézinet; France Mentré; Diane Descamps; Patrick Yeni
Journal:  J Antimicrob Chemother       Date:  2012-05-29       Impact factor: 5.790

3.  HIV-1 load comparison using four commercial real-time assays.

Authors:  Thomas Bourlet; Anne Signori-Schmuck; Laurent Roche; Vinca Icard; Henia Saoudin; Mary-Anne Trabaud; Jean-Claude Tardy; Patrice Morand; Bruno Pozzetto; René Ecochard; Patrice André
Journal:  J Clin Microbiol       Date:  2010-11-10       Impact factor: 5.948

4.  Comparative evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 version 2 test using the TaqMan 48 analyzer and the Abbott RealTime HIV-1 assay.

Authors:  Estrelita Janse van Rensburg; Karen Tait; Alistair Watt; Robert Schall
Journal:  J Clin Microbiol       Date:  2010-10-27       Impact factor: 5.948

5.  Standardization and performance evaluation of "modified" and "ultrasensitive" versions of the Abbott RealTime HIV-1 assay, adapted to quantify minimal residual viremia.

Authors:  Alessandra Amendola; Maria Bloisi; Patrizia Marsella; Rosella Sabatini; Angela Bibbò; Claudio Angeletti; Maria Rosaria Capobianchi
Journal:  J Clin Virol       Date:  2011-07-20       Impact factor: 3.168

6.  Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals.

Authors:  Hiroyu Hatano; Eric L Delwart; Philip J Norris; Tzong-Hae Lee; Torsten B Neilands; Colleen F Kelley; Peter W Hunt; Rebecca Hoh; Jeffrey M Linnen; Jeffrey N Martin; Michael P Busch; Steven G Deeks
Journal:  AIDS       Date:  2010-10-23       Impact factor: 4.177

7.  Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure.

Authors:  Franco Maggiolo; Annapaola Callegaro; Giuliana Cologni; Claudia Bernardini; Daniela Velenti; Giampietro Gregis; Giampaolo Quinzan; Laura Soavi; Nathalie Iannotti; Emanuele Malfatto; Sebastiano Leone
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-15       Impact factor: 3.731

8.  The significance of low-level plasma HIV viral load on COBAS TaqMan HIV-1 assays for patients with undetectable plasma viral load on COBAS Amplicor monitor version 1.5.

Authors:  Kaveh Manavi
Journal:  HIV Clin Trials       Date:  2008 Jul-Aug

9.  Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL.

Authors:  Timothy J Henrich; Brian R Wood; Daniel R Kuritzkes
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

10.  Improving Clinical Laboratory Efficiency: Introduction of Systems for the Diagnosis and Monitoring of HIV Infection.

Authors:  Marta Alvarez; Natalia Chueca; Vicente Guillot; María Del Carmen Bernal; Federico García
Journal:  Open Virol J       Date:  2012-11-30
View more
  9 in total

1.  Ability of two commercially available assays (Abbott RealTime HIV-1 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2.0) to quantify low HIV-1 RNA Levels (<1,000 copies/milliliter): comparison with clinical samples and NIBSC working reagent for nucleic acid testing assays.

Authors:  Alessandra Amendola; Patrizia Marsella; Maria Bloisi; Federica Forbici; Claudio Angeletti; Maria R Capobianchi
Journal:  J Clin Microbiol       Date:  2014-03-26       Impact factor: 5.948

2.  Evaluation of the Aptima HIV-1 Quant Dx Assay Using Plasma and Dried Blood Spots.

Authors:  Malaya K Sahoo; Vici Varghese; Elizabeth White; Meg Winslow; David A Katzenstein; Robert W Shafer; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2016-08-17       Impact factor: 5.948

3.  Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study.

Authors:  Elie Helou; Sheela Shenoi; Tassos Kyriakides; Marie-Louise Landry; Michael Kozal; Lydia Aoun Barakat
Journal:  J Int Assoc Provid AIDS Care       Date:  2016-11-30

4.  Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.

Authors:  Patrick Ryscavage; Sean Kelly; Jonathan Z Li; P Richard Harrigan; Babafemi Taiwo
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

5.  Limits of Detection and Limits of Infection: Quantitative HIV Measurement in the Era of U = U.

Authors:  Ethel D Weld
Journal:  J Appl Lab Med       Date:  2021-01-12

Review 6.  HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.

Authors:  Loredana Sarmati; Gabriella D'Ettorre; Saverio Giuseppe Parisi; Massimo Andreoni
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

7.  Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients.

Authors:  Laura Marije Hofstra; Tania Mudrikova; Arjen J Stam; Sigrid Otto; Kiki Tesselaar; Monique Nijhuis; Annemarie M J Wensing
Journal:  PLoS One       Date:  2014-10-29       Impact factor: 3.240

8.  A Simple Phosphate-Buffered-Saline-Based Extraction Method Improves Specificity of HIV Viral Load Monitoring Using Dried Blood Spots.

Authors:  A Tariro Makadzange; F Kathryn Boyd; Benjamin Chimukangara; Collen Masimirembwa; David Katzenstein; Chiratidzo E Ndhlovu
Journal:  J Clin Microbiol       Date:  2017-05-03       Impact factor: 5.948

Review 9.  Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease.

Authors:  Aurelio Cafaro; Antonella Tripiciano; Orietta Picconi; Cecilia Sgadari; Sonia Moretti; Stefano Buttò; Paolo Monini; Barbara Ensoli
Journal:  Vaccines (Basel)       Date:  2019-08-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.